Fabien Depis
Founder & Chief Executive Officer TregShield Bio
Fabien Depis, Ph.D. is Founder and CEO of TregShield Bio, developing next-generation organ-selective antibodies engineered to be systemically inactive and conditionally activated within I&I diseased tissues. With over 17 years advancing Treg-targeted therapies, he is an expert in Treg modulation across cancer and autoimmunity. He served as Program Leader and Co-Inventor of the CCR8-targeted tumor Treg antibody GS-1811 at Jounce Therapeutics, now in Phase 1 immuno-oncology development with Gilead. His experience spans TNFR2 at Merrimack, Foralumab (NovImmune), CEL383 (Celsius), DT101 (Dualyx), and Treg cell therapies as Head of Discovery at GentiBio. He trained at Harvard Medical School (Mathis/Benoist) and chairs the Treg Summit (2023-2025).
Seminars
- Investigating engineering Treg cells from CD4+ and iPSC precursors to understand the impact on efficacy
- Examining engineering strategies required to achieve durable Treg stability in vivo for long-term efficacy
- Engineering CAR-Tregs and Allogeneic Tregs for potential therapies of autoimmune and transplant disease
- Growth factor and durability support strategies for long term Treg persistence in patients
- Understand how Treg GMP and approval processes have evolved for 2026
- Sharing FDA interactions to reveal and combat manufacturing and regulatory approval challenges
- Identifying opportunities for accelerated regulatory progression amid regulatory changes
